Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Screening and receiving information for intimate partner violence in healthcare settings: a cross-sectional study of Arab and Jewish women of childbearing age in Israel.

Daoud N, Berger-Polsky A, Sergienko R, O'Campo P, Leff R, Shoham-Vardi I.

BMJ Open. 2019 Feb 21;9(2):e022996. doi: 10.1136/bmjopen-2018-022996.

2.

NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee pain.

Arsenault P, Chiche D, Brown W, Miller J, Treister R, Leff R, Walker P, Katz N.

Pain Rep. 2018 Oct 26;3(6):e696. doi: 10.1097/PR9.0000000000000696. eCollection 2018 Nov.

3.

Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis.

Gerber DE, Beg MS, Fattah F, Frankel AE, Fatunde O, Arriaga Y, Dowell JE, Bisen A, Leff RD, Meek CC, Putnam WC, Kallem RR, Subramaniyan I, Dong Y, Bolluyt J, Sarode V, Luo X, Xie Y, Schwartz B, Boothman DA.

Br J Cancer. 2018 Oct;119(8):928-936. doi: 10.1038/s41416-018-0278-4. Epub 2018 Oct 15.

4.

Supervised Machine-Learning Reveals That Old and Obese People Achieve Low Dapsone Concentrations.

Hall RG 2nd, Pasipanodya JG, Swancutt MA, Meek C, Leff R, Gumbo T.

CPT Pharmacometrics Syst Pharmacol. 2017 Aug;6(8):552-559. doi: 10.1002/psp4.12208. Epub 2017 Jul 13.

5.

Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.

Beg MS, Huang X, Silvers MA, Gerber DE, Bolluyt J, Sarode V, Fattah F, Deberardinis RJ, Merritt ME, Xie XJ, Leff R, Laheru D, Boothman DA.

J Surg Oncol. 2017 Jul;116(1):83-88. doi: 10.1002/jso.24624. Epub 2017 Mar 27.

6.

Safety, Pharmacokinetics, and Pharmacodynamics Study in Healthy Subjects of Oral NEO6860, a Modality Selective Transient Receptor Potential Vanilloid Subtype 1 Antagonist.

Brown W, Leff RL, Griffin A, Hossack S, Aubray R, Walker P, Chiche DA.

J Pain. 2017 Jun;18(6):726-738. doi: 10.1016/j.jpain.2017.01.009. Epub 2017 Feb 8. Erratum in: J Pain. 2017 Sep;18(9):1150-1151.

PMID:
28188907
7.

Raman Spectroscopy: A Sensitive and Specific Technique for Determining the Accuracy of Compounded Pharmaceutical Formulations.

Meek C, Hoe J, Evans J, Thurman R, Ashworth L, Leff R.

J Pediatr Pharmacol Ther. 2016 Sep-Oct;21(5):413-418.

8.

Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People.

Hall RG Nd, Pasipanodya JG, Meek C, Leff RD, Swancutt M, Gumbo T.

CPT Pharmacometrics Syst Pharmacol. 2016 Dec;5(12):674-681. doi: 10.1002/psp4.12146. Epub 2016 Nov 21.

9.

Development and Validation of an Inexpensive, Simple, and Rapid Technique for Measuring the Accuracy of Extemporaneously Compounded Pharmaceuticals.

Meek C, Rothardt A, Evans J, Thurman R, Ashworth L, Leff R.

Int J Pharm Compd. 2015 Jul-Aug;19(4):340-3.

PMID:
26625572
10.

Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.

Gerber DE, Boothman DA, Fattah FJ, Dong Y, Zhu H, Skelton RA, Priddy LL, Vo P, Dowell JE, Sarode V, Leff R, Meek C, Xie Y, Schiller JH.

Lung Cancer. 2015 Dec;90(3):534-41. doi: 10.1016/j.lungcan.2015.10.008. Epub 2015 Oct 9.

11.

Quantification of myo-inositol, 1,5-anhydro- D-sorbitol, and D-chiro-inositol using high-performance liquid chromatography with electrochemical detection in very small volume clinical samples.

Schimpf KJ, Meek CC, Leff RD, Phelps DL, Schmitz DJ, Cordle CT.

Biomed Chromatogr. 2015 Nov;29(11):1629-36. doi: 10.1002/bmc.3470. Epub 2015 May 26.

12.

Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.

Srivastava S, Pasipanodya J, Sherman CM, Meek C, Leff R, Gumbo T.

Antimicrob Agents Chemother. 2015 Apr;59(4):2273-9. doi: 10.1128/AAC.04441-14. Epub 2015 Feb 2.

13.

Demographic and clinical features of inclusion body myositis in North America.

Paltiel AD, Ingvarsson E, Lee DK, Leff RL, Nowak RJ, Petschke KD, Richards-Shubik S, Zhou A, Shubik M, O'Connor KC.

Muscle Nerve. 2015 Oct;52(4):527-33. doi: 10.1002/mus.24562. Epub 2015 Feb 17.

14.

Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations.

Gewandter JS, Dworkin RH, Turk DC, McDermott MP, Baron R, Gastonguay MR, Gilron I, Katz NP, Mehta C, Raja SN, Senn S, Taylor C, Cowan P, Desjardins P, Dimitrova R, Dionne R, Farrar JT, Hewitt DJ, Iyengar S, Jay GW, Kalso E, Kerns RD, Leff R, Leong M, Petersen KL, Ravina BM, Rauschkolb C, Rice AS, Rowbotham MC, Sampaio C, Sindrup SH, Stauffer JW, Steigerwald I, Stewart J, Tobias J, Treede RD, Wallace M, White RE.

Pain. 2014 Sep;155(9):1683-95. doi: 10.1016/j.pain.2014.05.025. Epub 2014 May 24. Review.

15.

Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.

Musuka S, Srivastava S, Siyambalapitiyage Dona CW, Meek C, Leff R, Pasipanodya J, Gumbo T.

Antimicrob Agents Chemother. 2013 Dec;57(12):5870-7. doi: 10.1128/AAC.00829-13. Epub 2013 Sep 16.

16.

Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths.

Hall RG 2nd, Swancutt MA, Meek C, Leff R, Gumbo T.

Antimicrob Agents Chemother. 2013 May;57(5):2259-64. doi: 10.1128/AAC.01490-12. Epub 2013 Mar 4.

17.

The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance.

Schmalstieg AM, Srivastava S, Belkaya S, Deshpande D, Meek C, Leff R, van Oers NS, Gumbo T.

Antimicrob Agents Chemother. 2012 Sep;56(9):4806-15. doi: 10.1128/AAC.05546-11. Epub 2012 Jul 2.

18.

The path forward: the future of graduate education in the pharmaceutical sciences: the report of the 2010-2011 Research and Graduate Affairs Committee.

Brueggemeier RW, Clark AM, Das SK, Forbes DS, Leff RD, Oie S, Sorofman BA, Thompson DF, Maine LL, Sagraves R.

Am J Pharm Educ. 2011 Dec 15;75(10):S13. doi: 10.5688/ajpe7510S13. No abstract available.

19.

Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people.

Hall RG 2nd, Swancutt MA, Meek C, Leff RD, Gumbo T.

Antimicrob Agents Chemother. 2012 Mar;56(3):1502-7. doi: 10.1128/AAC.05623-11. Epub 2011 Dec 12.

20.

Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.

Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T.

J Infect Dis. 2011 Dec 15;204(12):1951-9. doi: 10.1093/infdis/jir658. Epub 2011 Oct 21.

21.

Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling.

Srivastava S, Sherman C, Meek C, Leff R, Gumbo T.

Antimicrob Agents Chemother. 2011 Nov;55(11):5085-9. doi: 10.1128/AAC.00269-11. Epub 2011 Sep 6.

22.

Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Tagliabue C, Techasaensiri C, Torres JP, Katz K, Meek C, Kannan TR, Coalson JJ, Esposito S, Principi N, Leff R, Baseman JB, Hardy RD.

J Antimicrob Chemother. 2011 Oct;66(10):2323-9. doi: 10.1093/jac/dkr306. Epub 2011 Jul 25.

23.

Pharmacokinetics of oseltamivir according to trimester of pregnancy.

Greer LG, Leff RD, Rogers VL, Roberts SW, McCracken GH Jr, Wendel GD Jr, Sheffield JS.

Am J Obstet Gynecol. 2011 Jun;204(6 Suppl 1):S89-93. doi: 10.1016/j.ajog.2011.03.005. Epub 2011 Mar 9.

24.

Pharmacokinetics of oseltamivir in breast milk and maternal plasma.

Greer LG, Leff RD, Rogers VL, Roberts SW, McCracken GH Jr, Wendel GD Jr, Sheffield JS.

Am J Obstet Gynecol. 2011 Jun;204(6):524.e1-4. doi: 10.1016/j.ajog.2011.01.056. Epub 2011 Mar 31.

25.

Safety issues in the development of treatments for osteoarthritis: recommendations of the Safety Considerations Working Group.

Strand V, Bloch DA, Leff R, Peloso PM, Simon LS.

Osteoarthritis Cartilage. 2011 May;19(5):493-9. doi: 10.1016/j.joca.2011.02.019. Epub 2011 Mar 23.

26.

Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.

Deshpande D, Srivastava S, Meek C, Leff R, Hall GS, Gumbo T.

Antimicrob Agents Chemother. 2010 Jun;54(6):2534-9. doi: 10.1128/AAC.01761-09. Epub 2010 Apr 12.

27.

Ribavirin improves early responses to peginterferon through improved interferon signaling.

Feld JJ, Lutchman GA, Heller T, Hara K, Pfeiffer JK, Leff RD, Meek C, Rivera M, Ko M, Koh C, Rotman Y, Ghany MG, Haynes-Williams V, Neumann AU, Liang TJ, Hoofnagle JH.

Gastroenterology. 2010 Jul;139(1):154-62.e4. doi: 10.1053/j.gastro.2010.03.037. Epub 2010 Mar 17.

28.

Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium.

Deshpande D, Srivastava S, Meek C, Leff R, Gumbo T.

Antimicrob Agents Chemother. 2010 May;54(5):1728-33. doi: 10.1128/AAC.01355-09. Epub 2010 Mar 15.

29.

A formalized teaching, practice, and research partnership with the Veterans Affairs North Texas Health Care System: a model for advancing academic partnerships.

Hall RG 2nd, Foslein-Nash C, Singh DK, Zeiss RA, Sanders KM, Patry R, Leff R.

Am J Pharm Educ. 2009 Dec 17;73(8):141.

30.

Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol.

Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T.

J Infect Dis. 2010 Apr 15;201(8):1225-31. doi: 10.1086/651377.

31.
32.

Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Gumbo T, Dona CS, Meek C, Leff R.

Antimicrob Agents Chemother. 2009 Aug;53(8):3197-204. doi: 10.1128/AAC.01681-08. Epub 2009 May 18.

33.

Recommended education for pharmacists as competitive clinical scientists.

Dowling TC, Murphy JE, Kalus JS, Nkansah NT, Chappell JS, Wiederhold NP, Beringer P, Crews KR, Grabinski JL, Evens RP, Leff R; American College of Clinical Pharmacy.

Pharmacotherapy. 2009 Feb;29(2):236-44. doi: 10.1592/phco.29.2.236. No abstract available.

PMID:
19170592
34.

Evaluation of dosage form information provided in pediatric drug trial reports.

Haase MR, Luedtke S, Robles J, Parker T, Leff R, Giacoia G.

Int J Pharm Compd. 2009 Jan-Feb;13(1):14-8.

PMID:
23969957
35.

Ventricular free wall rupture: ten year survival after surgical repair.

Leff RA, Hoffman I.

Open Cardiovasc Med J. 2008;2:1-2. doi: 10.2174/1874192400802010001. Epub 2008 Jan 22.

36.

Predicting success in phase III studies from phase II results: a new paradigm is needed.

Leff R, Andrews M.

J Clin Oncol. 2008 Jul 20;26(21):3653-4; author reply 3654-5. doi: 10.1200/JCO.2008.17.5000. No abstract available.

PMID:
18640948
37.

Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.

Busti AJ, Bain AM, Hall RG 2nd, Bedimo RG, Leff RD, Meek C, Mehvar R.

J Cardiovasc Pharmacol. 2008 Jun;51(6):605-10. doi: 10.1097/FJC.0b013e31817b5b5a.

PMID:
18520949
38.

Classification of rheumatoid arthritis status with candidate gene and genome-wide single-nucleotide polymorphisms using random forests.

Sun YV, Cai Z, Desai K, Lawrance R, Leff R, Jawaid A, Kardia SL, Yang H.

BMC Proc. 2007;1 Suppl 1:S62. Epub 2007 Dec 18.

39.

How to achieve a high-performance health care system in the United States.

Leff RS.

Ann Intern Med. 2008 May 6;148(9):709-10; author reply 712. No abstract available.

PMID:
18458288
40.

Irinotecan-cisplatin therapy for patients with extensive-stage small cell lung cancer: use patterns among American medical oncologists 2000-2006.

Green MR, Dowlati A, Yellamraju L, Daniels L, Willey J, Andrews M, Leff R.

J Thorac Oncol. 2007 Oct;2(10):953-6.

41.

Practices of pharmacies that compound extemporaneous formulations.

Treadway AK, Craddock D, Leff R.

Am J Health Syst Pharm. 2007 Jul 1;64(13):1403-9.

PMID:
17592006
42.

Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone.

O'Dell JR, Elliott JR, Mallek JA, Mikuls TR, Weaver CA, Glickstein S, Blakely KM, Hausch R, Leff RD.

Arthritis Rheum. 2006 Feb;54(2):621-7.

43.

How do U.S. medical oncologists learn and apply new clinical trials information from press releases in nonmedical media? A case study based on ECOG 4599.

Dornbusch D, Allegra C, Willey J, Andrews M, Leff R, Epstein J, Jones J, Lokey L, Green MR.

Oncologist. 2006 Jan;11(1):31-8.

44.

Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis.

O'Dell JR, Petersen K, Leff R, Palmer W, Schned E, Blakely K, Haire C, Fernandez A.

J Rheumatol. 2006 Feb;33(2):213-8. Epub 2005 Dec 15.

PMID:
16358366
45.

COPD: clinical significance of early diagnosis.

Leff RD.

J Manag Care Pharm. 2005 Jul;11(6 Suppl A):S8-11; quiz S20-2. Review.

46.

Adjuvant Therapy Choices in Patients With Resected Non-Small-Cell Lung Cancer: Correlation of Doctors' Treatment Plans and Relevant Phase III Trial Data.

Green MR, Andrews M, Leff R, Willey J, Allegra C, Denes A, Epstein J, Jones J, Lokey L.

J Oncol Pract. 2005 Jul;1(2):37-42.

48.
49.

The effect of betamethasone on salivary estriol.

Leff RP, Goldkrand JW.

J Matern Fetal Neonatal Med. 2002 Mar;11(3):192-5.

PMID:
12380676
50.

Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.

O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G.

Arthritis Rheum. 2002 May;46(5):1164-70.

Supplemental Content

Support Center